tiprankstipranks
Trending News
More News >
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (HK:2315)
:2315
Hong Kong Market

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) Financial Statements

Compare
1 Followers

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Overview

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H's market cap is currently HK$4.73B. The company's EPS TTM is HK$0.092; its P/E ratio is 128.71; Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H is scheduled to report earnings on April 1, 2025, and the estimated EPS forecast is HK$0.01. See an overview of income statement, balance sheet, and cash flow financials.
Dec 23Dec 22Dec 21Dec 20
Income Statement
Total Revenue¥ 716.91M¥ 533.88M¥ 354.56M¥ 253.54M
Gross Profit¥ 506.03M¥ 391.75M¥ 247.44M¥ 166.99M
Operating Income¥ -270.29M¥ -606.00M¥ -525.45M¥ -380.26M
EBITDA¥ -97.87M¥ -413.31M¥ -378.12M¥ -318.44M
Net Income¥ -382.95M¥ -602.16M¥ -585.60M¥ -542.97M
Balance Sheet
Cash & Short-Term Investments¥ 434.04M¥ 611.27M¥ 566.45M¥ 950.04M
Total Assets¥ 2.45B¥ 2.80B¥ 2.30B¥ 2.33B
Total Debt¥ 544.11M¥ 415.28M¥ 538.35M¥ 463.80M
Net Debt¥ 144.51M¥ -187.79M¥ 71.91M¥ -286.25M
Total Liabilities¥ 1.66B¥ 1.65B¥ 1.05B¥ 868.28M
Stockholders' Equity¥ 785.89M¥ 1.15B¥ 1.25B¥ 1.45B
Cash Flow
Free Cash Flow¥ -203.26M¥ -543.94M¥ -564.45M¥ -531.73M
Operating Cash Flow¥ -76.65M¥ -303.27M¥ -365.78M¥ -225.31M
Investing Cash Flow¥ -100.28M¥ -153.74M¥ -84.13M¥ -188.18M
Financing Cash Flow¥ -37.82M¥ 587.20M¥ 219.44M¥ 868.44M
Currency in CNY

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Earnings and Revenue History

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Debt to Assets

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Cash Flow

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis